246 related articles for article (PubMed ID: 16177277)
21. Executive functioning component mechanisms and schizophrenia.
Kerns JG; Nuechterlein KH; Braver TS; Barch DM
Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
[TBL] [Abstract][Full Text] [Related]
22. Behavioral indices in antipsychotic drug discovery.
Porsolt RD; Moser PC; Castagné V
J Pharmacol Exp Ther; 2010 Jun; 333(3):632-8. PubMed ID: 20200119
[TBL] [Abstract][Full Text] [Related]
23. Treatment of cognitive deficits in schizophrenia.
Bowie CR; Harvey PD
Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
[TBL] [Abstract][Full Text] [Related]
24. [Cognitive remediation and cognitive assistive technologies in schizophrenia].
Sablier J; Stip E; Franck N
Encephale; 2009 Apr; 35(2):160-7. PubMed ID: 19393385
[TBL] [Abstract][Full Text] [Related]
25. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia.
Carter CS
Schizophr Bull; 2005 Oct; 31(4):810-5. PubMed ID: 16107584
[TBL] [Abstract][Full Text] [Related]
26. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
27. Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia.
Levin ED; Christopher NC
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):223-9. PubMed ID: 16356617
[TBL] [Abstract][Full Text] [Related]
28. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
29. Behavioral animal models to assess pro-cognitive treatments for schizophrenia.
Young JW; Amitai N; Geyer MA
Handb Exp Pharmacol; 2012; (213):39-79. PubMed ID: 23027412
[TBL] [Abstract][Full Text] [Related]
30. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.
Harvey PD; Green MF; Keefe RS; Velligan DI
J Clin Psychiatry; 2004 Mar; 65(3):361-72. PubMed ID: 15096076
[TBL] [Abstract][Full Text] [Related]
31. Developing drugs for cognitive impairment in schizophrenia.
Breier A
Schizophr Bull; 2005 Oct; 31(4):816-22. PubMed ID: 16150959
[TBL] [Abstract][Full Text] [Related]
32. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
Millan MJ; Brocco M
Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
[TBL] [Abstract][Full Text] [Related]
33. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature.
O'Brien AR; Chiaravalloti N; Goverover Y; Deluca J
Arch Phys Med Rehabil; 2008 Apr; 89(4):761-9. PubMed ID: 18374010
[TBL] [Abstract][Full Text] [Related]
34. Wayne Fenton's impact on academic neuroscience.
Geyer MA; Tamminga CA
Schizophr Bull; 2007 Sep; 33(5):1156-9. PubMed ID: 17617663
[TBL] [Abstract][Full Text] [Related]
35. [Measuring the cognitive deficit associated with schizophrenia: presentation of the MATRICS neuropsychological test battery].
Sarolta K; Pál C; István B
Neuropsychopharmacol Hung; 2007 Oct; 9(3):143-50. PubMed ID: 18399033
[TBL] [Abstract][Full Text] [Related]
36. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
Nuechterlein KH; Robbins TW; Einat H
Schizophr Bull; 2005 Oct; 31(4):870-4. PubMed ID: 16150960
[TBL] [Abstract][Full Text] [Related]
37. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.
Grayson B; Idris NF; Neill JC
Behav Brain Res; 2007 Nov; 184(1):31-8. PubMed ID: 17675172
[TBL] [Abstract][Full Text] [Related]
38. The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.
Feifel D; Melendez G; Priebe K; Shilling PD
Behav Brain Res; 2007 Aug; 181(2):278-86. PubMed ID: 17559953
[TBL] [Abstract][Full Text] [Related]
39. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
Karasawa J; Hashimoto K; Chaki S
Behav Brain Res; 2008 Jan; 186(1):78-83. PubMed ID: 17854919
[TBL] [Abstract][Full Text] [Related]
40. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism.
Terry AV; Mahadik SP
J Pharmacol Exp Ther; 2007 Mar; 320(3):961-8. PubMed ID: 16966470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
